Xenetic Biosciences, Inc.

Home
United States
Framingham, MA
Xenetic Biosciences, Inc.

XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Ltd.

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

03/13/2026

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

https://bit.ly/4sawQ2f

03/12/2026

Our proprietary platform is designed to address critical unmet needs across multiple solid tumor indications.

At , we’re advancing innovative approaches with the potential to expand treatment possibilities and provide hope.

03/05/2026

Want to stay updated on our DNase technologies?
Stay in the loop by signing up for our alerts here: https://bit.ly/3zXgBLd

02/24/2026

At Xenetic Bio, we are focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers.

02/10/2026

Subscribe to our email alerts to stay informed about our latest news and events: https://bit.ly/3zXgBLd

02/06/2026

February is . Early detection, prevention and continued research matter.

At , we are committed to advancing science that supports better outcomes for patients everywhere.

02/04/2026

On , we recognize the importance of awareness, research and global collaboration.

At , our mission is to advance science that supports better cancer care and patient outcomes.

01/28/2026

Early detection of pancreatic carcinoma remains a major challenge, as most patients are diagnosed at advanced stages.

We're dedicated to finding solutions to change that.

01/20/2026

We’re advancing a proprietary technology platform aimed at enhancing the effectiveness of immunotherapies, opening the door to new possibilities in cancer treatment and better outcomes for patients.

01/12/2026

As we advance our development strategy, is conducting exploratory studies to evaluate our lead program alongside chemo, radiation and immunotherapy across multiple indications.

01/02/2026

remains one of the most challenging and devastating cancers, with low survival rates and few effective treatment options.

At , we believe advancing innovative research is essential to improving outcomes and bringing new hope to patients.

12/31/2025

Wishing you a Happy New Year!

Here's to a 2026 filled with progress, innovation and new possibilities in oncology.

Address

40 Speen Street
Framingham, MA
01701

Telephone

+17817787720

Website

http://www.xeneticbio.com/

Alerts

Be the first to know and let us send you an email when Xenetic Biosciences, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Xenetic Biosciences, Inc.:

Want your practice to be the top-listed Clinic in Framingham?

Our Story

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.